15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 肝癌,肝移植 电子版] 最初用化疗栓塞治疗的乙型肝炎相关肝细胞癌的长 ...
查看: 702|回复: 2
go

[早中期肝癌] 电子版] 最初用化疗栓塞治疗的乙型肝炎相关肝细胞癌的长期 [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2019-7-18 21:01 |只看该作者 |倒序浏览 |打印


    Cancer Med. 2019 Jul 17. doi: 10.1002/cam4.2380. [Epub ahead of print]
    Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization.Chen ZX1,2,3, Jian ZW1,2,3, Wu XW1,2,3, Wang JC1,2,3, Peng JY1,2,3, Lao XM1,2,3.
    Author information1Department of Hepatobiliary and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.2State Key Laboratory of Southern China, Guangzhou, P. R. China.3Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China.

    AbstractOBJECTIVE:Transarterial chemoembolization (TACE) is recommended to treat intermediate/advanced stage of hepatocellular carcinoma (HCC). However, the overall survival among initially TACE-treated patients varies significantly. The clinical characterization of long-term survival following TACE remains uncertain. We sought to identify clinical parameters and treatment requirements for long-term survival among patients with hepatitis B-related HCC who were initially treated with TACE.
    MATERIALS AND METHODS:The included patients with HCC were admitted to our cancer center between December 2009 and May 2015. Patients who survived for >3 years were compared with those who died within 3 years. The clinical and laboratory findings that were associated with the survival were also analyzed.
    RESULTS:One in six (17.9%) patients with HCC in this cohort survived for > 3 years after TACE. Body mass index (BMI) ≥ 23kg/m2 , aspartate aminotransferase levels ≤ 40 U/L, an activated partial thromboplastin time ≤ 34 seconds, α-fetoprotein (AFP) levels ≤ 25 ng/mL, antiviral therapy, tumor size ≤ 8 cm, solitary nodule, and the absence of vascular invasion were independently favorably associated with a 3-year survival. An absence of vascular invasion was the only independent factor associated with 3-year survival in patients who received resection and/or ablation after TACE.
    CONCLUSION:In this cohort, a 3-year survival was associated with BMI, antivirus treatment, tumor status, hepatic function, and AFP level. Distant metastasis did not negatively impact the long-term survival among patients with hepatitis B-related HCC initially treated with TACE. Vascular invasion was the single impediment to long-term survival in patients who received add-on resection and/or ablation after TACE.

    © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.



    KEYWORDS:clinical characteristics; long-term survival; transarterial chemoembolization; treatments after chemoembolization

    PMID:31313476DOI:10.1002/cam4.2380


Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2019-7-18 21:01 |只看该作者
癌症医学。 2019年7月17日doi:10.1002 / cam4.2380。 [印刷前的电子版]
最初用化疗栓塞治疗的乙型肝炎相关肝细胞癌的长期存活的临床条件和治疗要求。
Chen ZX1,2,3,Jian ZW1,2,3,Wu XW1,2,3,Wang JC1,2,3,Peng JY1,2,3,Lao XM1,2,3。
作者信息

1
    中山大学肿瘤防治中心肝胆胰外科,广州,中国。
2
    中国南方国家重点实验室,广州,中国。
3
    广州癌症医学协同创新中心,中国。

抽象
目的:

推荐经动脉化疗栓塞(TACE)治疗肝细胞癌(HCC)的中晚期。然而,最初TACE治疗的患者的总体存活率差异显着。 TACE后长期存活的临床特征仍不确定。我们试图确定最初接受TACE治疗的乙型肝炎相关HCC患者的长期生存的临床参数和治疗要求。
材料和方法:

纳入的HCC患者于2009年12月至2015年5月期间入住我们的癌症中心。将存活3年以上的患者与3年内死亡的患者进行比较。还分析了与存活相关的临床和实验室发现。
结果:

在该组中,六分之一(17.9%)的HCC患者在TACE后存活> 3年。体重指数(BMI)≥23kg/ m2,天冬氨酸转氨酶水平≤40U/ L,活化部分促凝血酶原激酶时间≤34秒,甲胎蛋白(AFP)水平≤25ng/ mL,抗病毒治疗,肿瘤大小≤8cm ,孤立结节和血管侵犯的缺乏独立地有利于3年生存。在TACE后接受切除和/或消融的患者中,没有血管侵犯是与3年生存相关的唯一独立因素。
结论:

在该队列中,3年生存率与BMI,抗病毒治疗,肿瘤状态,肝功能和AFP水平相关。远处转移并未对最初用TACE治疗的乙型肝炎相关性HCC患者的长期存活率产生负面影响。血管侵犯是TACE后接受附加切除和/或消融的患者长期存活的唯一障碍。

©2019作者。癌症医学由John Wiley&Sons Ltd.出版。
关键词:

临床特征;长期生存;经动脉化疗栓塞;化疗栓塞后的治疗

结论:
    31313476
DOI:
    10.1002 / cam4.2380

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

3
发表于 2019-7-18 21:01 |只看该作者
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-23 05:16 , Processed in 0.013415 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.